BioMarin Pharmaceuticals (BMRN)

• Market cap: $12.8B
• 1 day: 0.00%
• 5 days: 0.67%
• 1 month: 1.43%
• 3 months: -3.54%
• 6 months: -18.12%
• Year to date: 1.34%
• 1 year: -29.73%
• 5 years: -26.04%
• 10 years: -30.23%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more call options, than puts

Call options by funds: $152M | Put options by funds: $112M

1% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 86

1% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 191

1% less funds holding

Funds holding: 548 [Q2] → 542 (-6) [Q3]

4.99% less ownership

Funds ownership: 99.4% [Q2] → 94.41% (-4.99%) [Q3]

19% less capital invested

Capital invested by funds: $15.5B [Q2] → $12.6B (-$2.91B) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $65 4% downside
• Avg. target: $91 34% upside
• High target: $109 62% upside

9 analyst ratings

• positive: 5 56%
• neutral: 4 44%
• negative: 0 0%

Cantor Fitzgerald Olivia Brayer 32% 1-year accuracy 7 / 22 met price target	34% upside $90	Overweight Reiterated	12 Dec 2024
Wolfe Research Akash Tewari 23% 1-year accuracy 3 / 13 met price target	41% upside $95	Outperform Initiated	15 Nov 2024
Citigroup David Lebovitz 76% 1-year accuracy 13 / 17 met price target	20% upside $81	Neutral Maintained	30 Oct 2024
Canaccord Genuity Whitney Ijem 30% 1-year accuracy 12 / 40 met price target	25% upside $84	Hold Maintained	30 Oct 2024
JP Morgan Jessica Fye 45% 1-year accuracy 17 / 38 met price target	62% upside $109	Overweight Maintained	30 Oct 2024